ArticleBMC medical imaging2025
Machine learning in CTEPH: predicting the efficacy of BPA based on clinical and echocardiographic features.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research advances in chronic thromboembolic pulmonary hypertension: from pathological mechanisms to multidisciplinary management.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study aims to develop a machine learning (ML)-based predictive model for evaluating the efficacy of percutaneous pulmonary balloon angioplasty (BPA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) by integrating clinical and echocardiographic parameters. By comparing the predictive performance of different algorithms, we aimed to establish a robust tool to identify patients most likely to benefit from BPA.
methodsWe retrospectively included 135 inoperable CTEPH patients who underwent BPA between January 2017 and September 2024. Clinical and echocardiographic data prior to the first BPA procedure were collected. The cohort was temporally split into a training set (2017–2021) and a test set (2022–2024). Key variables were identified using univariate logistic regression followed by Least Absolute Shrinkage and Selection Operator (LASSO) feature selection. Five ML models were trained to predict BPA response, defined as either a mean pulmonary artery pressure (mPAP) ≤ 30 mmHg or a ≥ 30% reduction in pulmonary vascular resistance (PVR) from baseline. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, F1 score, and Brier score. SHapley Additive exPlanations (SHAP) values were applied to interpret feature importance of the predictive model.
resultsA total of 135 patients were included to construct models. 6 features were selected from 49 variables for model training. The Logistic Regression with L2 regularisation method demonstrated the most optimal predictive efficacy, as evidenced by the highest AUC of 0.865 (95% CI: 0.710–0.985), with an accuracy of 0.848, sensitivity of 0.950, specificity of 0.692, an F1 score of 0.884, and a Brier score of 0.162 in the test set. According to SHAP, the most influential predictors for BPA response in patients with CTEPH were the proportion of occlusive lesions, tricuspid annular plane systolic excursion to pulmonary artery systolic pressure ratio(TAPSE/PASP), six-minute walk distance (6MWD), right ventricular end-systolic area (RVESA), the severity of tricuspid regurgitation (TR) and PVR.
conclusionsBy integrating clinical characteristics and echocardiographic parameters, an ML-based BPA efficacy prediction model was developed. Among all of the models, the Logistic Regression with L2 regularisation model exhibited the best overall performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.